Miami, FLORIDA6 Active Studies

Sarcoma Clinical Trials in Miami, FLORIDA

Find 6 actively recruiting sarcoma clinical trials in Miami, FLORIDA. Connect with local research sites and explore new treatment options.

6
Active Trials
6
Sponsors
825
Enrolling

Recruiting Sarcoma Studies in Miami

RecruitingMiami, FLORIDANCT05712694

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline....

300 participants
Polaris Group
View Study Details
RecruitingMiami, FLORIDANCT06797999

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01....

270 participants
Adcendo ApS
View Study Details
RecruitingMiami, FLORIDANCT06127407

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histo...

136 participants
Servier Bio-Innovation LLC
View Study Details
RecruitingMiami, FLORIDANCT05634369

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

The purpose of this study is to determine if the addition of infusions of a type of immune cell called a "natural killer", or NK cell to the sarcoma chemotherapy regimen GEM/DOX (gemcitabine and docet...

50 participants
Nationwide Children's Hospital
View Study Details
RecruitingMiami, FLORIDANCT04305691

Trial of Ixazomib for Kaposi Sarcoma

This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth....

41 participants
AIDS Malignancy Consortium
View Study Details
RecruitingMiami, FLORIDANCT04388839

Evolutionary Therapy for Rhabdomyosarcoma

This clinical trial will evaluate 4 different strategies of chemotherapy schedules in newly diagnosed participants with metastatic Fusion Positive (alveolar) Rhabdomyosarcoma. The participant and thei...

28 participants
H. Lee Moffitt Cancer Center and Research Institute
View Study Details

About Sarcoma Clinical Trials in Miami

Sarcomas are rare cancers that arise in bone and soft tissues including muscle, fat, blood vessels, and connective tissue. There are more than 70 subtypes of sarcoma. Treatment usually involves surgery combined with radiation and/or chemotherapy.

There are currently 6 sarcoma clinical trials recruiting participants in Miami, FLORIDA. These studies are seeking a combined 825 participants. Research is being sponsored by Polaris Group, Adcendo ApS, Servier Bio-Innovation LLC and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Sarcoma Clinical Trials in Miami — FAQ

Are there sarcoma clinical trials in Miami?

Yes, there are 6 sarcoma clinical trials currently recruiting in Miami, FLORIDA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Miami?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Miami research site will contact you about next steps.

Are clinical trials in Miami free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Miami studies also compensate for your time and travel.

What sarcoma treatments are being tested?

The 6 active trials in Miami are testing new therapies including novel drugs, biologics, and treatment approaches for sarcoma.

Data updated March 2, 2026 from ClinicalTrials.gov